U.S. and Biotech Industry Hold Different Views on China’s Growing Role

The quick emergence of China as one of the major players in biotechnology has led to increasing controversy in the United States. Even though the American pharmaceutical sector sees China as a potential source of innovations, research, and new medicines, US policymakers have become more and more worried about the issues of national and biosecurity.

These contrasting concerns give rise to tension between the state administration and the biotech community. Collaboration with Chinese partners appears to be a good strategy for expanding product line and cutting the cost of the development process, while US officials are only concerned about securing the research activities and decreasing the dependence on foreign biotechnology.

Government Tightens Oversight of China-Related Biotech Activities

On the other hand, initiatives to reduce the country’s reliance on Chinese biotech companies have been consistently proposed by the U.S. government. Among such initiatives can be mentioned, for instance, the implementation of the BIOSECURE Act in 2025. The law limits federal contracts with Chinese biotech companies which present any threats to national security. Although the law which has eventually passed was less radical compared to previous drafts, it nevertheless pushed pharmaceutical companies to look for alternative sources in China.

In the realm of trade, the Section 232 investigation related to pharmaceutical sector was launched during the presidency of Donald Trump in order to assess the security consequences of the country’s reliance on medicines and active pharmaceutical ingredients imported from foreign nations. It should be noted that some companies have succeeded in avoiding heavy tariffs through negotiations with the White House.

Congressional Scrutiny Increases Over Clinical Trials in China

Further concerns have been raised following the sending of letters by John Moolenaar, the Chairman of the House Select Committee on China, to the executives of major pharmaceutical companies such as Eli Lilly, Pfizer, Merck, Bristol Myers Squibb, and AbbVie.

These letters raised doubts regarding the clinical trials being conducted by these pharmaceutical firms in China because the results of these trials could be used in the development of military biotech in China. Congress wants more information about the measures in place for data protection and diligence, as well as clinical trials being done in military hospitals and Xinjiang in China.

Should they receive unsatisfactory answers, Congress might push for further legislation limiting some clinical trials in China.

Industry Warns Against Limiting Global Research Partnerships

The leaders of the biotech industry claim that just by limiting collaboration with China, the root cause of the problem will remain unsolved.

Currently, China is a very good place to carry out clinical trials because it will take much less time and will cost much cheaper than if the same trial would take place in the US. Losing all of these options without developing some competitive solutions domestically may result in slower innovation and new medicine development.

As John Crowley, president and CEO of BIO, puts it, the United States should try not to limit collaboration but rather improve its biotech system through the use of more competitive policies.

Federal Agencies Push to Strengthen U.S. Innovation

The Department of Health and Human Services as well as the FDA have started making efforts to promote clinical research in the country.

At the BIO International Convention 2026, the FDA launched an investigational new drug pilot program aimed at speeding up early-stage research conducted in the domestic territory. The representatives of the agency said that the initiative is being implemented by a number of federal agencies, namely NIH, NCI, and CMS, who try to cope with growing numbers of foreign clinical trials.

Funding Concerns Could Undermine U.S. Leadership

Despite all this, it is believed that certain actions taken by the government could undermine the country’s position in the future. For example, decreased NIH funding for research and possible changes in the management of grants from the government have already been criticized by research institutions since this might hinder scientific progress and development of new drugs.

It is thought that it is necessary for the country to adopt a well-thought-out strategy in order to boost innovation in the country without compromising national security. Unless there is more coordination between the government and the biotechnology industry, China will continue to increase its presence in the biotechnology market.